
Photo taken from Jayastu Senapati/X
May 21, 2024, 04:55
Jayastu Senapati: Optimal use of Azacytidine Venetoclax in AML Patients in Indian Scenario
Jayastu Senapati, Assistant Professor of Leukemia at MD Anderson Cancer Center, shared a post on X:
“Looking forward to discussing the optimal use of Hypomethylating Agent (HMA) – Venetoclax in patients with Acute Myeloid Leukaemia (AML), focussing on Indian/Low and Middle-Income Country (LMIC) settings- May 17, CT 8:30AM (IST 7PM).”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 21, 2025, 15:06
Feb 21, 2025, 14:27
Feb 21, 2025, 14:13
Feb 21, 2025, 13:29